Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Teva Pharmaceutical and OncoGenex announces top-line survival results of phase III SYNERGY Trial Evaluating Custirsen in Combination with First-line Docetaxel and Prednisone


Monday, 28 Apr 2014 07:00am EDT 

Teva Pharmaceutical Industries Ltd and OncoGenex Pharmaceuticals, Inc:Results from Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer.Top-line survival results indicate addition of custirsen to standard first-line docetaxel/prednisone therapy did not meet the primary endpoint of statistically significant improvement in overall survival (OS) in men with metastatic CRPC.Says compared to docetaxel/prednisone alone (median survival 23.4 months vs 22.2 months, respectively, hazard ratio 0.93 and one-sided p-value 0.207). 

Company Quote

56.27
-0.89 -1.56%
1:40pm EST